Evidence map›Paper›PMID 29635383›Full record

Trial reportArchives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists2019

Attention Measures of Accuracy, Variability, and Fatigue Detect Early Response to Donepezil in Alzheimer's Disease: A Randomized, Double-blind, Placebo-Controlled Pilot Trial.

Clara Vila-Castelar, Jenny J Ly, Lillian Kaplan, Kathleen Van Dyk, Jeffrey T Berger, Lucy O Macina, Jennifer L Stewart, Nancy S Foldi

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03073876 (Detecting an Early Response to Donepezil With Measures of Visual Attention), which is not on this map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03073876 phase4completednot on this map

Detecting an Early Response to Donepezil With Measures of Visual Attention

TypeinterventionalSponsorNYU Langone HealthRan2005 to 2021Enrolled25ConditionsAlzheimer DiseaseArmsDonepezil Hydrochloride, Placebo
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Stress, Asthenia, and Cognitive Disorders.Neuroscience and behavioral physiology · 2022
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Clara Vila-CastelarDepartment of Psychology, Queens College and The Graduate Center, City University of New York, New York, NY, USA.
Jenny J LyeResearch Technology, Inc., Boston, MA, USA.
Lillian KaplanDepartment of Occupational Therapy, York College, City University of New York, New York, NY, USA.
Kathleen Van DykDepartment of Psychiatry, UCLA - Semel Institute for Neuroscience & Human Behavior and Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
Jeffrey T BergerDivision of Palliative Medicine and Bioethics, Department of Medicine, NYU Winthrop Hospital, Mineola, NY, USA.
Lucy O MacinaDivision of Geriatrics, Department of Medicine, NYU Winthrop Hospital, Mineola, NY, USA.
Jennifer L StewartDepartment of Psychology, Queens College and The Graduate Center, City University of New York, New York, NY, USA.
Nancy S FoldiDepartment of Psychology, Queens College and The Graduate Center, City University of New York, New York, NY, USA.
The Graduate Center, CUNY · USWinthrop-University Hospital · USQueens University of Charlotte · USUCLA Jonsson Comprehensive Cancer CenterYork College, City University of New York · US

Funding

Serial position effect as an evidence-based cognitive marker in Alzheimer diseaseSC3GM122662 · NIGMS · QUEENS COLLEGE · PI FOLDI, NANCY SUZANNE · 2017 to 2020
$462k
NIGMS NIH HHS SC3 GM122662
6 · The paper itself

Abstract

objectiveDonepezil is widely used to treat Alzheimer's disease (AD), but detecting early response remains challenging for clinicians. Acetylcholine is known to directly modulate attention, particularly under high cognitive conditions, but no studies to date test whether measures of attention under high load can detect early effects of donepezil. We hypothesized that load-dependent attention tasks are sensitive to short-term treatment effects of donepezil, while global and other domain-specific cognitive measures are not.

methodThis longitudinal, randomized, double-blind, placebo-controlled pilot trial (ClinicalTrials.gov Identifier: NCT03073876) evaluated 23 participants newly diagnosed with AD initiating de novo donepezil treatment (5 mg). After baseline assessment, participants were randomized into Drug (n = 12) or Placebo (n = 11) groups, and retested after approximately 6 weeks. Cognitive assessment included: (a) attention tasks (Foreperiod Effect, Attentional Blink, and Covert Orienting tasks) measuring processing speed, top-down accuracy, orienting, intra-individual variability, and fatigue; (b) global measures (Alzheimer's Disease Assessment Scale-Cognitive Subscale, Mini-Mental Status Examination, Dementia Rating Scale); and (c) domain-specific measures (memory, language, visuospatial, and executive function).

resultsThe Drug but not the Placebo group showed benefits of treatment at high-load measures by preserving top-down accuracy, improving intra-individual variability, and averting fatigue. In contrast, other global or cognitive domain-specific measures could not detect treatment effects over the same treatment interval.

conclusionsThe pilot-study suggests that attention measures targeting accuracy, variability, and fatigue under high-load conditions could be sensitive to short-term cholinergic treatment. Given the central role of acetylcholine in attentional function, load-dependent attentional measures may be valuable cognitive markers of early treatment response.

Indexed as

FatigueAgedAged, 80 and overAlzheimer DiseaseAttentionCholinesterase InhibitorsDonepezilDouble-Blind MethodExecutive FunctionFemaleHumansMaleMemoryMiddle AgedNeuropsychological TestsPilot ProjectsCholinesterase InhibitorsDonepezilAlzheimer dementiaAttentionCholinesterase inhibitorsDonepezilTreatment outcome

Identifiers

PMID29635383
PMCPMC6487534
OpenAlexW2796946945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.